- Catalogue N°
- 852.110.000 - 200µg / 200µl
852.110.005 - 500µg / 500µl
- Target species
- Recognises the Gp130, common subunit for IL-6, IL-11, OSM, LIF, CNTF, CT-1 receptors, a 130-140 kDa protein
- Flow Cytometry
- Functional assay
- Western Blot
- Myeloma X63/AG.8653 x Balb/c spleen cells
- Natural soluble gp130
- 200µg or 500µg (Discovery Size also available please enquire)
- Mouse IgG1 Kappa light chain
- Phosphate-buffered saline. Sterile-filtered through 0.22 μm and treated to remove endotoxins. Carrier and preservative free
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
- Biological Activity
- Activates cells carrying gp130. Induces gp130 activation, Jak 1, Jak 2, Stat 1 and Stat 3 phosphorylation
Glycoprotein 130 (also known as gp130, IL6ST, IL6-beta or CD130) is a transmembrane protein which is the founding member of the class of all cytokine receptors. It forms one subunit of the type I cytokine receptor within the IL-6 receptor family. The IL-6 receptor complex mediating the biological activities consists of two distinct membrane-bound glycoproteins:
- IL-6 Receptor (IL-6R, gp80) is 80 kDa alpha subunit, transmembrane glycoprotein that is 449 aa long. It binds IL-6 with low affinity
- gp130 the signal-transducing non-ligand binding 130 kDa component (gp130) that is required for high-affinity binding complex (Kd = 50 pM)
It is often referred to as the common gp130 subunit, and is important for signal transduction following cytokine engagement. As with other type I cytokine receptors, gp130 possesses a WSXWS amino acid motif that ensures correct protein folding and ligand binding. It interacts with Janus kinases to elicit an intracellular signal following receptor interaction with its ligand. Structurally, gp130 is composed of five fibronectin type-III domains and one immunoglobulin-like C2-type (immunoglobulin-like) domain in its extracellular portion.
Soluble IL-6 receptor (sIL-6R) is a 50-55 kDa ligand binding protein, derived from the extracellular part of the gp80 receptor by either proteolytic cleavage or by alternative splicing. The soluble form of IL-6R can bind its ligand and induce cellular responses by association with gp130, thus acting as an IL-6 agonist.
Dysregulated production of IL6 and its receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Elevated IL-6 concentrations have been reported in numerous clinical disorders where they appear to orchestrate a variety of inflammatory responses.
Version 9 - 06.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.